These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30178825)

  • 1. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia.
    Zhou B; Wang P; Xu WJ; Li YM; Tong DL; Jiang J; Sun ZY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5077-5081. PubMed ID: 30178825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of IPSS with IL-8 and COX-2 levels in patients with benign prostatic hyperplasia and prostatitis].
    Chen DA; Yang XZ; Zhang PH; Li GS; Chang DG
    Zhonghua Nan Ke Xue; 2013 Jun; 19(6):527-30. PubMed ID: 23862231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients.
    Qu X; Huang Z; Meng X; Zhang X; Dong L; Zhao X
    Int Urol Nephrol; 2014 Mar; 46(3):499-504. PubMed ID: 24022843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis].
    Ren X; Wu C; Yu Q; Zhu F; Liu P; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):135-9. PubMed ID: 26806754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?
    Schenk JM; Hunter-Merrill R; Zheng Y; Etzioni R; Gulati R; Tangen C; Thompson IM; Kristal AR
    Am J Epidemiol; 2013 Sep; 178(5):741-51. PubMed ID: 23813705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway.
    Yang T; Zhou Y; Wang H; Chen S; Shen M; Hu Y; Wang T; Liu J; Jiang Z; Wang Z; Zhu X; Qian S; Yin X; Lu Q
    Exp Cell Res; 2020 Sep; 394(1):112145. PubMed ID: 32561286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial.
    Zendehdel A; Ansari M; Khatami F; Mansoursamaei S; Dialameh H
    Clin Nutr; 2021 May; 40(5):3325-3331. PubMed ID: 33213976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.
    Kim WT; Yun SJ; Choi YD; Kim GY; Moon SK; Choi YH; Kim IY; Kim WJ
    J Korean Med Sci; 2011 Sep; 26(9):1214-8. PubMed ID: 21949470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.
    Abotsi E; Adanu KK; Bansah EC
    Afr J Prim Health Care Fam Med; 2022 Dec; 14(1):e1-e6. PubMed ID: 36546488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men.
    Zhang X; Zeng X; Liu Y; Dong L; Zhao X; Qu X
    Urol Int; 2014; 93(2):214-9. PubMed ID: 24862628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
    Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
    Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do patients with familial benign prostatic hyperplasia differ clinically from those with sporadic benign prostatic hyperplasia?
    Oztekin CV; Oztürk B; Taş M; Uğurlu O; Cetinkaya M
    Urol Int; 2006; 76(4):332-4. PubMed ID: 16679835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.